Theranostic applications of phage display to control leishmaniasis: selection of biomarkers for serodiagnostics, vaccination, and immunotherapy

Coelho, Eduardo Antônio Ferraz; Chávez-Fumagalli, Miguel Á.; Costa, Lourena E.; Tavares, Carlos Alberto Pereira; Soto, Manuel; Goulart, Luiz Ricardo

doi:10.1590/0037-8682-0096-2015

Cited by 23 publications

(19 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The phage-display libraries are one of the most effective ways to generate a great number of peptides, proteins, or antibodies in a small period [ 90 ]. They have been proved useful in the analysis of several autoimmune diseases [ 130 , 131 ] and to produce human antibody therapeutics [ 132 ], such as Helicobacter pylori [ 133 ], P. aeruginosa [ 134 ], S. aureus [ 135 ], Leishmania [ 136 ], Citomegalovirus [ 137 ] and Rabies virus [ 138 ], among others. However, this technology has a few limitations, like the diversity of the peptides and their quality, which depends on the origin and diversity of the library, as well as on the process employed to evaluate the antibodies [ 139 ].…”

Section: Discussionmentioning

confidence: 99%

Viral Related Tools against SARS-CoV-2

Fernández-García

Pacios

González-Bardanca

et al. 2020

Viruses

View full text Add to dashboard Cite

At the end of 2019, a new disease appeared and spread all over the world, the COVID-19, produced by the coronavirus SARS-CoV-2. As a consequence of this worldwide health crisis, the scientific community began to redirect their knowledge and resources to fight against it. Here we summarize the recent research on viruses employed as therapy and diagnostic of COVID-19: (i) viral-vector vaccines both in clinical trials and pre-clinical phases; (ii) the use of bacteriophages to find antibodies specific to this virus and some studies of how to use the bacteriophages themselves as a treatment against viral diseases; and finally, (iii) the use of CRISPR-Cas technology both to obtain a fast precise diagnose of the patient and also the possible use of this technology as a cure.

show abstract

Section: Discussionmentioning

confidence: 99%

Viral Related Tools against SARS-CoV-2

Fernández-García

Pacios

González-Bardanca

et al. 2020

Viruses

View full text Add to dashboard Cite

show abstract

“…Phage display has been successfully utilized to identify serum biomarkers in non-CNS disorders including ankylosing spondylitis (Wang et al, 2011), rheumatoid and osteoarthritis (Weng et al, 2012) (Araujo et al, 2015), heart disease (Park et al, 2010), hepatocellular carcinoma (Zhang et al, 2011), and lieshmaniasis (Coelho et al, 2015), and to identify a novel calpain inhibitor (Guttmann et al, 2005) but has not previously been applied to CNS disorders including TBI. Our results extend the utility of phage display to the discovery of serum TBI biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Phage display for identification of serum biomarkers of traumatic brain injury

Ghoshal

Bondada

Saatman

et al. 2016

Journal of Neuroscience Methods

View full text Add to dashboard Cite

Background The extent and severity of traumatic brain injuries (TBIs) can be difficult to determine with current diagnostic methods. To address this, there has been increased interest in developing biomarkers to assist in the diagnosis, determination of injury severity, evaluation of recovery and therapeutic efficacy, and prediction of outcomes. Several promising serum TBI biomarkers have been identified using hypothesis-driven approaches, largely examining proteins that are abundant in neurons and non-neural cells in the CNS. New Method An unbiased approach, phage display, was used to identify serum TBI biomarkers. In this proof-of-concept study, mice received a TBI using the controlled cortical impact model of TBI (1 mm injury depth, 3.5 m/s velocity) and phage display was utilized to identify putative serum biomarkers at 6h postinjury. Results An engineered phage which preferentially bound to injured serum was sequenced to identify the 12-mer ‘recognizer’ peptide expressed on the coat protein. Following synthesis of the recognizer peptide, pull down, and mass spectrometry analysis, the target protein was identified as glial fibrillary acidic protein (GFAP). Comparison with Existing Methods and Conclusions GFAP has previously been identified as a promising TBI biomarker. The results provide proof of concept regarding the ability of phage display to identify TBI serum biomarkers. This methodology is currently being applied to serum biomarkers of mild TBI.

show abstract

“…The list is even broader and even more applications are expected to arise as the methodology evolves. [58][59][60][61][62][63][64][65][66][67]…”

Section: Why Use Recombinant Phages?mentioning

confidence: 99%

Genetically modified bacteriophages

et al. 2016

View full text Add to dashboard Cite

Phages or bacteriophages, viruses that infect and replicate inside bacteria, are the most abundant microorganisms on earth. The realization that antibiotic resistance poses a substantial risk to the world's health and global economy is revitalizing phage therapy as a potential solution. The increasing ease by which phage genomes can be modified, owing to the influx of new technologies, has led to an expansion of their natural capabilities, and a reduced dependence on phage isolation from environmental sources. This review will discuss the way synthetic biology has accelerated the construction of genetically modified phages and will describe the wide range of their applications. It will further provide insight into the societal and economic benefits that derive from the use of recombinant phages in various sectors, from health to biodetection, biocontrol and the food industry.

show abstract

Theranostic applications of phage display to control leishmaniasis: selection of biomarkers for serodiagnostics, vaccination, and immunotherapy

Cited by 23 publications

References 81 publications

Viral Related Tools against SARS-CoV-2

Viral Related Tools against SARS-CoV-2

Phage display for identification of serum biomarkers of traumatic brain injury

Genetically modified bacteriophages

Contact Info

Product

Resources

About